CRISPR Therapeutics vs Prime Medicine
Prime Medicine reported revenue of $5 million in fiscal 2025, 1.3 times CRISPR Therapeutics' $4 million in fiscal 2025. CRISPR Therapeutics' revenue fell 90.6% in its latest year, and Prime Medicine's grew 55.3%. CRISPR Therapeutics had an operating margin of -18933.7%, against -4498.1% at Prime Medicine. Free cash flow was −$346 million at CRISPR Therapeutics and −$167 million at Prime Medicine.
Side by side
| CRISPR Therapeutics | Prime Medicine | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $4M | $5M |
| Revenue growth | −90.6% | 55.3% |
| Revenue growth a year, last 5 years | 38.0% | −2.4% |
| Gross margin | — | — |
| Operating margin | −18,933.7% | −4,498.1% |
| Net margin | −16,569.8% | −4,342.4% |
| Free cash flow | −$346M | −$167M |
| Free cash flow margin | −9,855.5% | −3,607.4% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 6.6% | 25.4% |
| Last close | $42.24 | $4.27 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $14.5 million | — |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
CRISPR TherapeuticsPrime Medicine
Operating margin
Percent of revenue
CRISPR TherapeuticsPrime Medicine
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CRISPR TherapeuticsPrime Medicine
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the CRISPR Therapeutics and Prime Medicine pages.